# Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel

> **NCT02439346** · PHASE1 · TERMINATED · sponsor: **Bayer** · enrollment: 15 (actual)

## Conditions studied

- Medical Oncology

## Interventions

- **DRUG:** BAY1143269 tablet

## Key facts

- **NCT ID:** NCT02439346
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06-15
- **Primary completion:** 2017-03-27
- **Final completion:** 2017-04-24
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Study stopped due to project prioritization
- **Last updated:** 2018-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02439346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02439346, "Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02439346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*